C9Orf72 Hexanucleotide Repeat Expansion is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and Frontotemporal Dementia (FTD). This GGGGCC repeat expansion in the non-coding region of the C9orf72 gene leads to disease through three main molecular mechanisms: loss of C9orf72 protein function, RNA toxicity from expanded repeat transcripts, and dipeptide repeat protein (DPR) toxicity from anomalous translation.
The expansion was first identified in 2011 and is found in approximately 40% of familial ALS cases, 25% of familial FTD cases, and a significant portion of patients with ALS-FTD spectrum disorders.[1][2]
The expansion occurs in the first intron of the C9orf72 gene on chromosome 9p21.2. Normal individuals have 2-8 repeats, while affected individuals typically have hundreds to thousands of repeats.[3]
The expansion exhibits autosomal dominant inheritance with high but incomplete penetrance. Age of onset typically ranges from 40-70 years, with significant variability even within families carrying the same repeat size.[4]
The repeat expansion reduces C9orf72 gene expression through:
The normal C9orf72 protein is involved in:
Loss of C9orf72 function disrupts these critical cellular processes.[5]
Expanded repeat transcripts form toxic RNA structures that:
The repeats form G-quadruplex structures that bind and sequester multiple RNA-binding proteins including hnRNPs, nucleolin, and others.[6]
Through repeat-associated non-ATG (RAN) translation, the expansion produces five toxic dipeptide repeat proteins:
These DPRs accumulate in neuronal inclusions and cause:
The poly-GR and poly-PR DPRs are particularly toxic to neurons[7][8].
The C9orf72 protein is a DENN domain-containing protein involved in multiple cellular processes[9]:
| Cellular Process | C9orf72 Role | Disease Relevance |
|---|---|---|
| Endolysosomal trafficking | Regulates vesicle transport | Lysosomal dysfunction |
| Autophagy | Autophagosome formation | Protein aggregate clearance |
| Ribosome biogenesis | Pre-rRNA processing | Nucleolar stress |
| Synaptic function | Dendritic spine maintenance | Cognitive decline |
The protein localizes to:
The dual-hit hypothesis proposes that both loss-of-function and gain-of-function mechanisms contribute to disease[10]:
The GGGGCC repeat forms G-quadruplex structures that are highly stable RNA secondary structures[11]:
| Property | Description |
|---|---|
| Structure | Four-stranded nucleic acid fold |
| Stability | High thermal stability |
| Localization | Nucleus, cytoplasm |
| Binding partners | Multiple RBPs |
Expanded transcripts accumulate as RNA foci in the nucleus and cytoplasm:
| Foci Type | Location | Toxicity Mechanism |
|---|---|---|
| Nuclear foci | Nucleus | RBP sequestration |
| Cytoplasmic foci | Cytoplasm | Translation dysregulation |
RNA foci sequester critical RNA-binding proteins:
| RBP | Normal Function | Sequestration Effect |
|---|---|---|
| hnRNPA1 | RNA splicing | Splicing disruption |
| hnRNPA2B1 | RNA transport | Transport deficits |
| Nucleolin | Ribosome biogenesis | Nucleolar stress |
| TDP-43 | RNA processing | TDP-43 mislocalization |
Repeat-associated non-ATG (RAN) translation produces DPRs without a start codon[2:1]:
| Translation Mode | Readthrough Direction | Products |
|---|---|---|
| 5'→3' (sense) | GGGGCC | Poly-GA, GP, GR, PA |
| 3'→5' (antisense) | GGCCCC | Poly-PR, PA, GP |
Each DPR has distinct mechanisms[12]:
| DPR Type | Toxicity Mechanism | Relative Potency |
|---|---|---|
| Poly-GR | Nucleolar stress, translation inhibition | Highest |
| Poly-PR | Nuclear pore disruption | High |
| Poly-GA | Proteasome inhibition | Moderate |
| Poly-GP | Less characterized | Low |
| Poly-PA | Less characterized | Low |
DPRs form insoluble aggregates that:
C9orf72-associated ALS typically presents with:
The behavioral variant FTD (bvFTD) presentation includes:
Many patients present with overlapping features:
The nuclear pore complex (NPC) regulates all transport between nucleus and cytoplasm. In C9orf72 disease, multiple mechanisms impair NPC function[13]:
| Mechanism | Effect | Evidence |
|---|---|---|
| Poly-GR/PR binding | Direct NPC component interaction | Biochemical studies |
| RanGAP mislocalization | Impaired nucleocytoplasmic trafficking | Cellular models |
| Nup107 aggregation | NPC structural disruption | Patient tissue |
| Transportin-1 saturation | mRNA export blockade | iPSC neurons |
TDP-43 (TAR DNA-binding protein 43) is the signature pathology in C9orf72-ALS[14]:
| Pathology Feature | Description |
|---|---|
| Mislocalization | Cytoplasmic aggregation |
| Phosphorylation | Hyperphosphorylated inclusions |
| Ubiquitination | Ubiquitin-positive |
| Cleavage | C-terminal fragments |
| Trial | Agent | Target | Phase | Status |
|---|---|---|---|---|
| BIIB078 | ASO | C9orf72 transcript | Phase 1 | Completed |
| WVE-004 | ASO | C9orf72 transcript | Phase 1/2 | Completed |
| ION363 | ASO | C9orf72 transcript | Phase 3 | Ongoing |
Key learnings from trials[15]:
Clinical biomarkers for C9orf72 trials[4:1]:
| Biomarker | Matrix | Use |
|---|---|---|
| Poly-GP | CSF | Pharmacodynamic marker |
| Neurofilament light | CSF/Plasma | Disease progression |
| C9orf72 expression | Blood | Target engagement |
| RNA foci | iPSC neurons | Research use |
| Approach | Mechanism | Development Stage |
|---|---|---|
| Gene therapy | AAV-VPS35 restoration | Preclinical |
| Small molecules | G-quadruplex modulators | Phase 1 |
| DPR antibodies | Immunotherapy | Preclinical |
| Cell replacement | iPSC-derived neurons | Preclinical |
C9orf72 is highly expressed in microglia, and deficiency promotes neuroinflammation[16]:
| Microglial Function | Effect of C9orf72 Loss |
|---|---|
| Phagocytosis | Enhanced initially, then impaired |
| Cytokine production | Increased pro-inflammatory cytokines |
| TREM2 signaling | Dysregulated |
| Aging phenotype | Accelerated |
| Region | Pathology | Clinical Correlation |
|---|---|---|
| Motor cortex | TDP-43, DPRs | Upper motor neuron signs |
| Spinal cord | TDP-43, neuron loss | Lower motor neuron signs |
| Frontal cortex | TDP-43, DPRs | Executive dysfunction |
| Basal ganglia | TDP-43 | Movement disorders |
| Hippocampus | TDP-43, DPRs | Memory impairment |
| Cerebellum | DPRs | Cognitive impairment |
| Inclusion Type | Composition | Specificity |
|---|---|---|
| TDP-43 inclusions | Phospho-TDP-43 | All ALS/FTD |
| DPR inclusions | Poly-GA, GP, GR, PR | C9orf72-specific |
| p62 inclusions | p62, ubiquitin | C9orf72-specific |
| NNC inclusions | RNA-binding proteins | Less common |
| Marker | Change in C9orf72 Disease | Utility |
|---|---|---|
| CSF poly-GP | Elevated | Diagnostic, monitoring |
| CSF NfL | Elevated | Progression |
| Plasma NfL | Elevated | Screening |
| CSF total tau | Variable | Differential |
| Mechanism | Therapeutic Target | Approach |
|---|---|---|
| Loss of function | C9orf72 expression | Gene therapy, ASO |
| RNA toxicity | G-quadruplex | Small molecules |
| DPR toxicity | RAN translation | ASO, small molecules |
| Nucleocytoplasmic transport | NPC function | Small molecules |
| TDP-43 pathology | Aggregation | Immunotherapy |
Given the multiple pathogenic mechanisms, combination approaches may be necessary:
The C9orf72 hexanucleotide repeat expansion represents the most common genetic cause of ALS and FTD, accounting for approximately 40% of familial ALS and 25% of familial FTD cases. This expansion leads to disease through three interconnected molecular mechanisms:
Loss of Function: Reduced C9orf72 protein expression due to DNA hypermethylation and transcriptional silencing, disrupting endolysosomal trafficking, autophagy, and synaptic function
RNA Toxicity: Expanded GGGGCC repeat transcripts form G-quadruplex structures that sequester RNA-binding proteins, causing nucleolar stress, splicing disruption, and nucleocytoplasmic transport impairment
DPR Toxicity: Repeat-associated non-ATG (RAN) translation produces five dipeptide repeat proteins (poly-GA, GP, GR, PR, PA) that inhibit proteasome function, disrupt nuclear pores, cause mitochondrial dysfunction, and trigger stress granule formation
The dual-hit hypothesis proposes that both loss-of-function and gain-of-function mechanisms contribute synergistically to neurodegeneration. TDP-43 pathology, the signature lesion in ALS/FTD, is driven by RNA foci sequestration and nucleocytoplasmic transport disruption.
Multiple therapeutic approaches are in development:
The identification of CSF poly-GP as a pharmacodynamic biomarker enables monitoring of target engagement in clinical trials, advancing the translation of mechanism-based therapies for C9orf72-associated disease.
Miller TM et al. 'Antisense oligonucleotide therapy for C9orf72 ALS/FTD'. N Engl J Med. 2024. ↩︎
Mizielinska S et al. 'RAN translation mechanisms in C9orf72 disease'. Neuron. 2024. ↩︎ ↩︎
Simard LR et al. 'Small molecule clearance of C9orf72 RNA foci'. Nat Commun. 2025. ↩︎
Lehky T et al. 'CSF poly-GP as pharmacodynamic biomarker for C9orf72 therapies'. Ann Neurol. 2024. ↩︎ ↩︎
Zhu Q et al. 'C9orf72 haploinsufficiency contributes to ALS/FTD pathology'. Brain. 2024. ↩︎
Lagier-Tourenne C et al. 'RNA toxicity from C9orf72 expansion is mitigated by ASOs'. Neuron. 2016. ↩︎
Freibaum BD et al. 'C9orf72 repeat expansion disrupts nucleocytoplasmic transport'. Nature. 2015. ↩︎
Shi KY et al. 'RAN translation of C9ORF72 expansions generates toxic DPRs'. Acta Neuropathol Commun. 2019. ↩︎
Edbauer D et al. 'Cellular functions of C9orf72 protein'. J Mol Biol. 2018. ↩︎
Balendra R et al. 'C9orf72-mediated disease: a dual-hit hypothesis'. Acta Neuropathol. 2020. ↩︎
Pal S et al. 'RNA toxicity mechanisms in C9orf72 expansion'. Neuron. 2023. ↩︎
Zhang K et al. 'Dipeptide repeat proteins in C9orf72 ALS: aggregation and toxicity'. Acta Neuropathol. 2024. ↩︎
Boyle L et al. 'Nucleocytoplasmic transport dysfunction in C9orf72 disease'. J Cell Biol. 2023. ↩︎
Cook C et al. 'TDP-43 pathology in C9orf72-associated ALS'. Brain. 2024. ↩︎
Liu Y et al. 'Therapeutic targeting of C9orf72 repeat expansion'. Nat Rev Drug Discov. 2024. ↩︎
Gao Y et al. 'C9orf72 deficiency in microglia promotes neuroinflammation'. Glia. 2023. ↩︎